{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:56:08Z","timestamp":1791820568874,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020897","name":"NACTRC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020897","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mitochondrial long-chain fatty acid oxidation and carnitine metabolism defects are a group of inherited metabolic diseases. We performed a retrospective cohort study to report on the phenotypic and genotypic spectrum of mitochondrial long-chain fatty acid oxidation and carnitine metabolism defects as well as their treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients with mitochondrial long-chain fatty acid oxidation and carnitine metabolism defects were included. We divided patients into two groups to compare outcomes of those treated symptomatically (SymX) and asymptomatically (AsymX). We reviewed patient charts for clinical features, biochemical investigations, molecular genetic investigations, cardiac assessments, neuroimaging, treatments, and outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 38 patients including VLCAD (<jats:italic>n<\/jats:italic>\u2009=\u20095), LCHAD (<jats:italic>n<\/jats:italic>\u2009=\u20094), CACT (<jats:italic>n<\/jats:italic>\u2009=\u20093), MAD (<jats:italic>n<\/jats:italic>\u2009=\u20091), CPT-I (<jats:italic>n<\/jats:italic>\u2009=\u200913), CPT-II (<jats:italic>n<\/jats:italic>\u2009=\u20093) deficiencies and CTD (<jats:italic>n<\/jats:italic>\u2009=\u20099). Fourteen patients were diagnosed symptomatically (SymX), and 24 patients were diagnosed asymptomatically (AsymX). Twenty-eight variants in seven genes were identified in 36 patients (pathogenic\/likely pathogenic<jats:italic>n<\/jats:italic>\u2009=\u200925; variant of unknown significance<jats:italic>n<\/jats:italic>\u2009=\u20093). Four of those variants were novel. All patients with LCHAD deficiency had the common variant (p.Glu474Gln) in<jats:italic>HADHA<\/jats:italic>and their phenotype was similar to the patients reported in the literature for this genotype. Only one patient with VLCAD deficiency had the common p.Val283Ala in<jats:italic>ACADVL.<\/jats:italic>The different genotypes in the SymX and AsymX groups for VLCAD deficiency presented with similar phenotypes. Eight patients were treated with carnitine supplementation [CTD (<jats:italic>n<\/jats:italic>\u2009=\u20096), CPT-II (<jats:italic>n<\/jats:italic>\u2009=\u20091), and MAD (<jats:italic>n<\/jats:italic>\u2009=\u20091) deficiencies]. Thirteen patients were treated with a long-chain fat restricted diet and MCT supplementation. A statistically significant association was found between rhabdomyolysis, and hypoglycemia in the SymX group compared to the AsymX group. A higher number of hospital admissions, longer duration of hospital admissions and higher CK levels were observed in the SymX group, even though the symptomatic group was only 37% of the study cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Seven different mitochondrial long-chain fatty acid oxidation and carnitine metabolism defects were present in our study cohort. In our clinic, the prevalence of mitochondrial long-chain fatty acid oxidation and carnitine defects was 4.75%.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-022-02512-5","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T19:02:27Z","timestamp":1663268547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Outcomes of mitochondrial long chain fatty acid oxidation and carnitine defects from a single center metabolic genetics clinic"],"prefix":"10.1186","volume":"17","author":[{"given":"Anastasia","family":"Ambrose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Athey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailly","family":"Ghai-Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-6764","authenticated-orcid":false,"given":"Saadet","family":"Mercimek-Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"2512_CR1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.17925\/EE.2021.17.2.108","volume":"17","author":"JJ Baker","year":"2021","unstructured":"Baker JJ, Burton BK. Diagnosis and clinical management of long-chain fatty-acid oxidation disorders: a review. touchREV Endocrinol. 2021;17:108\u201311.","journal-title":"touchREV Endocrinol"},{"key":"2512_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.pcl.2017.11.006","volume":"65","author":"A El-Gharbawy","year":"2018","unstructured":"El-Gharbawy A, Vockley J. Inborn errors of metabolism with myopathy: defects of fatty acid oxidation and the carnitine shuttle system. Pediatr Clin North Am. 2018;65:317\u201335.","journal-title":"Pediatr Clin North Am"},{"issue":"Suppl 3","key":"2512_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000448321","volume":"68","author":"N Longo","year":"2016","unstructured":"Longo N. Primary carnitine deficiency and newborn screening for disorders of the carnitine cycle. Ann Nutr Metab. 2016;68(Suppl 3):5\u20139.","journal-title":"Ann Nutr Metab"},{"key":"2512_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10545-010-9090-x","volume":"33","author":"U Spiekerkoetter","year":"2010","unstructured":"Spiekerkoetter U. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis. 2010;33:527\u201332.","journal-title":"J Inherit Metab Dis"},{"key":"2512_CR5","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/jimd.12371","volume":"44","author":"B Ryder","year":"2021","unstructured":"Ryder B, Inbar-Feigenberg M, Glamuzina E, Halligan R, Vara R, Elliot A, Coman D, et al. New insights into carnitine-acylcarnitine translocase deficiency from 23 cases: management challenges and potential therapeutic approaches. J Inherit Metab Dis. 2021;44:903\u201315.","journal-title":"J Inherit Metab Dis"},{"key":"2512_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/8904_2017_58","volume":"40","author":"A Obaid","year":"2018","unstructured":"Obaid A, Nashabat M, Alfadhel M, Alasmari A, Al Mutairi F, Alswaid A, Faqeih E, et al. Clinical, biochemical, and molecular features in 37 saudi patients with very long chain acyl CoA dehydrogenase deficiency. JIMD Rep. 2018;40:47\u201353.","journal-title":"JIMD Rep"},{"key":"2512_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s13023-021-02126-3","volume":"16","author":"Y Lin","year":"2021","unstructured":"Lin Y, Lin B, Chen Y, Zheng Z, Fu Q, Lin W, Zhang W. Biochemical and genetic characteristics of patients with primary carnitine deficiency identified through newborn screening. Orphanet J Rare Dis. 2021;16:503.","journal-title":"Orphanet J Rare Dis"},{"key":"2512_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10545-016-0004-4","volume":"40","author":"YE Landau","year":"2017","unstructured":"Landau YE, Waisbren SE, Chan LM, Levy HL. Long-term outcome of expanded newborn screening at Boston children\u2019s hospital: benefits and challenges in defining true disease. J Inherit Metab Dis. 2017;40:209\u201318.","journal-title":"J Inherit Metab Dis"},{"key":"2512_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ymgme.2017.06.015","volume":"122","author":"NM Gallant","year":"2017","unstructured":"Gallant NM, Leydiker K, Wilnai Y, Lee C, Lorey F, Feuchtbaum L, Tang H, Carter J, Enns GM, Packman S, Lin HJ, Wilcox WR, Cederbaum SD, Abdenur JE. Biochemical characteristics of newborns with carnitine transporter defect identified by newborn screening in California. Mol Genet Metab. 2017;122:76\u201384.","journal-title":"Mol Genet Metab"},{"key":"2512_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021944","volume":"99","author":"M Ding","year":"2020","unstructured":"Ding M, Liu R, Qiubo L, Zhang Y, Kong Q. Neonatal-onset multiple acyl-CoA dehydrogenase deficiency (MADD) in the ETFDH gene: a case report and a literature review. Medicine. 2020;99: e21944.","journal-title":"Medicine"},{"key":"2512_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1542\/peds.109.1.99","volume":"109","author":"ME den Boer","year":"2002","unstructured":"den Boer ME, Wanders RJ, Morris AA, IJlst L, Heymans HS, Wijburg FA. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics. 2002;109:99\u2013104.","journal-title":"Pediatrics"},{"key":"2512_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/jimd.12037","volume":"42","author":"JC Bleeker","year":"2019","unstructured":"Bleeker JC, Kok IL, Ferdinandusse S, van der Pol WL, Cuppen I, Bosch AM, Langeveld M, et al. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes. J Inherit Metab Dis. 2019;42:414\u201323.","journal-title":"J Inherit Metab Dis"},{"key":"2512_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2015.10.009","volume":"20","author":"T Immonen","year":"2016","unstructured":"Immonen T, Ahola E, Toppila J, Lapatto R, Tyni T, Lauronen L. Peripheral neuropathy in patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: a follow-up EMG study of 12 patients. Eur J Paediatr Neurol. 2016;20:38\u201344.","journal-title":"Eur J Paediatr Neurol"},{"key":"2512_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10545-017-0041-7","volume":"40","author":"M Bellusci","year":"2017","unstructured":"Bellusci M, Quijada-Fraile P, Barrio-Carreras D, Martin-Hernandez E, Garcia-Silva M, Merinero B, Perez B, et al. Carnitine palmitoyltransferase 1A deficiency: abnormal muscle biopsy findings in a child presenting with Reye\u2019s syndrome. J Inherit Metab Dis. 2017;40:751\u20132.","journal-title":"J Inherit Metab Dis"},{"key":"2512_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.12997\/jla.2020.9.3.313","volume":"9","author":"RJA Wanders","year":"2020","unstructured":"Wanders RJA, Visser G, Ferdinandusse S, Vaz FM, Houtkooper RH. Mitochondrial fatty acid oxidation disorders: laboratory diagnosis, pathogenesis, and the complicated route to treatment. J Lipid Atheroscler. 2020;9:313\u201333.","journal-title":"J Lipid Atheroscler"},{"key":"2512_CR16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s10545-009-1125-9","volume":"32","author":"U Spiekerkoetter","year":"2009","unstructured":"Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, Das A, et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis. 2009;32:488\u201397.","journal-title":"J Inherit Metab Dis"},{"key":"2512_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10545-010-9188-1","volume":"33","author":"U Spiekerkoetter","year":"2010","unstructured":"Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis. 2010;33:555\u201361.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 7","key":"2512_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.37765\/ajmc.2020.88480","volume":"26","author":"J Vockley","year":"2020","unstructured":"Vockley J. Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care. 2020;26(Suppl 7):147\u201354.","journal-title":"Am J Manag Care"},{"key":"2512_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2022.04.001","volume":"136","author":"J Vockley","year":"2022","unstructured":"Vockley J, Enns GM, Ramirez AN, Bedrosian CL, Reineking B, Lu X, Ray K, et al. Response to triheptanoin therapy in critically ill patients with LC-FAOD: report of patients treated through an expanded access program. Mol Genet Metab. 2022;136:152\u201362.","journal-title":"Mol Genet Metab"},{"key":"2512_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jimd.12313","volume":"44","author":"J Vockley","year":"2021","unstructured":"Vockley J, Burton B, Berry G, Longo N, Phillips J, Sanchez-Valle A, Chapman K, et al. Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: results from an open-label, long-term extension study. J Inherit Metab Dis. 2021;44:253\u201363.","journal-title":"J Inherit Metab Dis"},{"key":"2512_CR21","doi-asserted-by":"publisher","first-page":"598760","DOI":"10.3389\/fgene.2020.598760","volume":"11","author":"E Sklirou","year":"2021","unstructured":"Sklirou E, Alodaib AN, Dobrowolski SF, Mohsen AA, Vockley J. Physiological perspectives on the use of triheptanoin as anaplerotic therapy for long chain fatty acid oxidation disorders. Front Genet. 2021;11:598760.","journal-title":"Front Genet"},{"key":"2512_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"2512_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O\u2019Donnell-Luria AH, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285\u201391.","journal-title":"Nature"},{"key":"2512_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymgme.2009.12.015","volume":"100","author":"NC Lee","year":"2010","unstructured":"Lee NC, Tang NL, Chien YH, Chen CA, Lin SJ, Chiu PC, Huang AC, et al. Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. Mol Genet Metab. 2010;100:46\u201350.","journal-title":"Mol Genet Metab"},{"key":"2512_CR25","doi-asserted-by":"publisher","first-page":"E1632","DOI":"10.1002\/humu.21311","volume":"31","author":"FY Li","year":"2010","unstructured":"Li FY, El-Hattab AW, Bawle EV, Boles RG, Schmitt ES, Scaglia F, Wong LJ. Molecular spectrum of SLC22A5 (OCTN2) gene mutations detected in 143 subjects evaluated for systemic carnitine deficiency. Hum Mutat. 2010;31:E1632\u201351.","journal-title":"Hum Mutat"},{"key":"2512_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ymgme.2010.07.013","volume":"101","author":"SA Collins","year":"2010","unstructured":"Collins SA, Sinclair G, McIntosh S, Bamforth F, Thompson R, Sobol I, Osborne G, et al. Carnitine palmitoyltransferase 1A (CPT1A) P479L prevalence in live newborns in Yukon, Northwest Territories, and Nunavut. Mol Genet Metab. 2010;101:200\u20134.","journal-title":"Mol Genet Metab"},{"key":"2512_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/pch\/pxaa039","volume":"26","author":"SA Collins","year":"2020","unstructured":"Collins SA, Hildes-Ripstein GE, Thompson JR, Edmunds S, Miners A, Rockman-Greenberg C, Arbour L. Neonatal hypoglycemia and the CPT1A P479L variant in term newborns: a retrospective cohort study of Inuit newborns from Kivalliq Nunavut. Paediatr Child Health. 2020;26:218\u201327.","journal-title":"Paediatr Child Health"},{"key":"2512_CR28","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.bbih.2020.100104","volume":"6","author":"G Preston","year":"2020","unstructured":"Preston G, Emmerzaal T, Kirdar F, Schrader L, Henckens M, Morava E, Kozicz T. Cerebellar mitochondrial dysfunction and concomitant multi-system fatty acid oxidation defects are sufficient to discriminate PTSD-like and resilient male mice. Brain Behav Immun Health. 2020;6:100104.","journal-title":"Brain Behav Immun Health"},{"key":"2512_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1743-7075-7-30","volume":"7","author":"JL Flanagan","year":"2010","unstructured":"Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutr Metab. 2010;7:30.","journal-title":"Nutr Metab"},{"key":"2512_CR30","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1210\/jc.2018-00953","volume":"103","author":"KL Madsen","year":"2018","unstructured":"Madsen KL, Preisler N, Rasmussen J, Hedermann G, Olesen JH, Lund AM, Vissing J. L-carnitine improves skeletal muscle fat oxidation in primary carnitine deficiency. J Clin Endocrinol Metab. 2018;103:4580\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"2512_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/cts.13133","volume":"15","author":"R Stenlid","year":"2022","unstructured":"Stenlid R, Olsson D, Cen J, Manell H, Haglind C, Chowdhury AI, Bergsten P, et al. Altered mitochondrial metabolism in peripheral blood cells from patients with inborn errors of \u03b2-oxidation. Clin Transl Sci. 2022;15:182\u201394.","journal-title":"Clin Transl Sci"},{"key":"2512_CR32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/0148607106030004286","volume":"30","author":"A Buenestado","year":"2006","unstructured":"Buenestado A, Cortijo J, Sanz MJ, Naim-Abu-Nabah Y, Martinez-Losa M, Mata M, Issekutz AC, Mart\u00ed-Bonmat\u00ed E, et al. Olive oil-based lipid emulsion\u2019s neutral effects on neutrophil functions and leukocyte-endothelial cell interactions. J Parenter Enteral Nutr. 2006;30:286\u201396.","journal-title":"J Parenter Enteral Nutr"},{"key":"2512_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00075197-199803000-00003","volume":"1","author":"P Yaqoob","year":"1998","unstructured":"Yaqoob P. Lipids and the immune response. Curr Opin Clin Nutr Metab Care. 1998;1:153\u201361.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2512_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ymgme.2018.06.012","volume":"125","author":"TN Tarasenko","year":"2018","unstructured":"Tarasenko TN, Cusmano-Ozog K, McGuire PJ. Tissue acylcarnitine status in a mouse model of mitochondrial \u03b2-oxidation deficiency during metabolic decompensation due to influenza virus infection. Mol Genet Metab. 2018;125:144\u201352.","journal-title":"Mol Genet Metab"},{"key":"2512_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.100632","volume":"24","author":"A Maguolo","year":"2020","unstructured":"Maguolo A, Rodella G, Dianin A, Nurti R, Monge I, Rigotti E, Cantalupo G, et al. Diagnosis, genetic characterization and clinical follow up of mitochondrial fatty acid oxidation disorders in the new era of expanded newborn screening: a single centre experience. Mol Genet Metab Rep. 2020;24: 100632.","journal-title":"Mol Genet Metab Rep"},{"key":"2512_CR36","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3390\/nu13092925","volume":"13","author":"K R\u00fccklov\u00e1","year":"2021","unstructured":"R\u00fccklov\u00e1 K, Hrub\u00e1 E, Pavl\u00edkov\u00e1 M, Han\u00e1k P, Farolfi M, Chrastina P, Vl\u00e1\u0161kov\u00e1 H, et al. Impact of newborn screening and early dietary management on clinical outcome of patients with long chain 3-hydroxyacyl-coa dehydrogenase deficiency and medium chain Acyl-CoA dehydrogenase deficiency-a retrospective nationwide study. Nutrients. 2021;13:2925.","journal-title":"Nutrients"},{"key":"2512_CR37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymgme.2016.05.007","volume":"118","author":"LD Pena","year":"2016","unstructured":"Pena LD, van Calcar SC, Hansen J, Edick MJ, Walsh Vockley C, Leslie N, Cameron C, et al. Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database. Mol Genet Metab. 2016;118:272\u201381.","journal-title":"Mol Genet Metab"},{"key":"2512_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ymgme.2015.08.011","volume":"116","author":"MJ Miller","year":"2015","unstructured":"Miller MJ, Burrage LC, Gibson JB, Strenk ME, Lose EJ, Bick DP, Elsea SH, et al. Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain Acyl-CoA dehydrogenase (VLCAD) deficiency in the United States. Mol Genet Metab. 2015;116:139\u201345.","journal-title":"Mol Genet Metab"},{"key":"2512_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ymgme.2016.05.012","volume":"118","author":"M Evans","year":"2016","unstructured":"Evans M, Andresen BS, Nation J, Boneh A. VLCAD deficiency: follow-up and outcome of patients diagnosed through newborn screening in Victoria. Mol Genet Metab. 2016;118:282\u20137.","journal-title":"Mol Genet Metab"},{"key":"2512_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/8904_2017_40","volume":"39","author":"B Merinero","year":"2018","unstructured":"Merinero B, Alcaide P, Mart\u00edn-Hern\u00e1ndez E, Morais A, Garc\u00eda-Silva MT, Quijada-Fraile P, Pedr\u00f3n-Giner C, et al. Four years\u2019 experience in the diagnosis of very long\u2013chain acyl-CoA dehydrogenase deficiency in infants detected in three Spanish newborn screening centers. JIMD Rep. 2018;39:63\u201374.","journal-title":"JIMD Rep"},{"key":"2512_CR41","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41436-020-01070-0","volume":"23","author":"D Marsden","year":"2021","unstructured":"Marsden D, Bedrosian CL, Vockley J. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders. Genet Med. 2021;23:816\u201329.","journal-title":"Genet Med"},{"key":"2512_CR42","doi-asserted-by":"publisher","first-page":"100884","DOI":"10.1016\/j.ymgmr.2022.100884","volume":"32","author":"CC Lim","year":"2022","unstructured":"Lim CC, Vockley J, Ujah O, Kirby RS, Edick MJ, Berry SA, Arnold GL. Outcomes and genotype correlations in patients with mitochondrial trifunctional protein or isolated long chain 3-hydroxyacyl-CoA dehydrogenase deficiency enrolled in the IBEM-IS database. Mol Genet Metab Rep. 2022;32:100884.","journal-title":"Mol Genet Metab Rep"},{"key":"2512_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF02185756","volume":"97","author":"I Handig","year":"1996","unstructured":"Handig I, Dams E, Taroni F, Van Laere S, de Barsy T, Willems PJ. Inheritance of the S113L mutation within an inbred family with carnitine palmitoyltransferase enzyme deficiency. Hum Genet. 1996;97:291\u20133.","journal-title":"Hum Genet"},{"key":"2512_CR44","first-page":"1697","volume-title":"Myology","author":"S Di Mauro","year":"1986","unstructured":"Di Mauro S, Papadimitriou A. Camitine palmitoyltransferase deficiency. In: Engel AG, Banker BQ, editors. Myology. 1st ed. New York: McGraw-Hill; 1986. p. 1697\u2013708.","edition":"1"},{"issue":"6","key":"2512_CR45","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1086\/301628","volume":"61","author":"M Huizing","year":"1997","unstructured":"Huizing M, Iacobazzi V, Ijlst L, Savelkoul P, Ruitenbeek W, van den Heuvel L, Indiveri C, Smeitink J, Trijbels F, Wanders R, Palmieri F. Cloning of the human carnitine-acylcarnitine carrier cDNA and identification of the molecular defect in a patient. Am J Hum Genet. 1997;61(6):1239\u201345.","journal-title":"Am J Hum Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02512-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:47:47Z","timestamp":1701046067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02512-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2512"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02512-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"19 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Ethics Office, Health Research Ethics Board, University of Alberta (Study ID: Pro00108842) approved this retrospective cohort study.All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}